The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance

Affiliations

¹ Clinical Epidemiology Program, Division of Rheumatology, Allergy, and Immunology, Mongan Institute, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
² Rheumatologist, Crystal Run Health, Middletown, NY.
³ Division of Rheumatology, Beth Israel Deaconess Medical Center, and Program in Rheumatology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
⁴ University of Queensland Faculty of Medicine, Brisbane, Queensland, Australia.
⁵ Department of Rheumatology, HealthPartners, St Paul, MN, USA.
⁶ Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton.
⁷ Canadian Arthritis Patient Alliance, Toronto, ON, Canada.
⁸ Division of Rheumatology, University of California, San Francisco, CA, USA.
⁹ Department of Medicine and Department of Pathology and Molecular Medicine, University of Otago, Wellington, New Zealand.

Editorial

Zachary S Wallace et al. Rheumatology (Oxford). 2020.

. 2020 Jun 1;59(6):1204-1206.

doi: 10.1093/rheumatology/keaa191.

¹ Clinical Epidemiology Program, Division of Rheumatology, Allergy, and Immunology, Mongan Institute, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
² Rheumatologist, Crystal Run Health, Middletown, NY.
³ Division of Rheumatology, Beth Israel Deaconess Medical Center, and Program in Rheumatology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
⁴ University of Queensland Faculty of Medicine, Brisbane, Queensland, Australia.
⁵ Department of Rheumatology, HealthPartners, St Paul, MN, USA.
⁶ Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton.
⁷ Canadian Arthritis Patient Alliance, Toronto, ON, Canada.
⁸ Division of Rheumatology, University of California, San Francisco, CA, USA.
⁹ Department of Medicine and Department of Pathology and Molecular Medicine, University of Otago, Wellington, New Zealand.

No abstract available

Figures

1. Fauci AS, Lane HC, Redfield RR.. Covid-19—navigating the uncharted. N Engl J Med 2020. Feb 28;382:1268–9. - PMC - PubMed
1. Emanuel EJ, Persad G, Upshur R. et al. Fair allocation of scarce medical resources in the time of Covid-19. N Engl J Med 2020; doi: 10.1056/NEJMsb2005114. [Epub ahead of print]. - PubMed
1. Dong H, Du H, Gardner L.. An Interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020; doi: 10.1016/S1473-3099(20)30120-1. [Epub ahead of print]. - PMC - PubMed
1. Yao X, Ye F, Zhang M. et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; doi: 10.1093/cid/ciaa237. [Epub ahead of print]. - PMC - PubMed
1. Mehta P, McAuley DF, Brown M. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; doi: 10.1016/S0140-6736(20)30628-0. [Epub ahead of print]. - PMC - PubMed